Tuberculosis Drugs Market Overview, Market Restraints and Drive growth in R&D Investment
- Get link
- X
- Other Apps
Tuberculosis Drugs Market |
Tuberculosis is a chronic disease that has spread over the world. Drug companies are concentrating their efforts on creating medications that can reduce the length of treatment and help overcome the hurdles of drug-susceptible and drug-resistant TB. There are two forms of TB treatment: first-line treatment, second-line treatment, and drug-resistant treatment.
Although
advanced technologies and the development of novel therapies are expected to
reduce the time it takes to treat tuberculosis, most cases can take up to 6
months to treat with currently available drugs. Despite existing medicines and
ongoing TB treatment drug advances, patients' access to suitable TB medicines
continues to be a challenge, particularly in the areas of multidrug-resistant TB
and paediatric TB.
Increasing R&D Investments and
New Drug Developments Are Expected to Drive Growth of the Tuberculosis Drugs
Market
The tuberculosis
drugs market is growing as a result of an increasing number of drug
innovations. The TB Alliance, a nonprofit group based in the United States, has
produced a novel medicine for treating tuberculosis that is very
treatment-resistant. For example, TB Alliance got FDA clearance in August 2019
for Pretomnid, a bedaquiline and linezolid combination regimen designed and
intended for the treatment of individuals with XDR-TB, or intolerant
non-responsive MDR-TB.
Furthermore,
in order to commercialise their newly produced pharmaceuticals, industry
companies are focused on strategic collaborations. In April 2019, for example,
Mylan, a pharmaceutical company, teamed up with the TB Alliance to
commercialise the Pretomanid medication for the treatment of pulmonary
tuberculosis (TB).
Tuberculosis Drugs Market –
Restraints
The rising number of medicine recalls is a key stumbling block to the market's expansion. Manufacturers of tuberculosis drugs face obstacles such as an increase in product recalls due to packaging or manufacturing defects. In India, for example, Sandoz recalled a batch of tuberculosis (TB) medications due to improper packaging. Furthermore, the Philippines Food and Medicine Administration recalled Novartis' drug Onecure in 2016 due to an insufficient amount of rifampicin in the drug.
Furthermore,
the growing prevalence of tuberculosis (TB) around the world is propelling the Tuberculosis
Drugs market forward. According to the World Health Organization's
Global Tuberculosis Report 2018, over 10 million persons worldwide were
infected with tuberculosis in 2017.
- Get link
- X
- Other Apps
Comments
Post a Comment